SCHEMBL3023940

SCHEMBL3023940

CC1CCN(C(=O)n2nnc3nc(Cl)ccc32)CC1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 6/20 0.40
FAAH O00519 5/20 0.40
JUN P05412 1/20 0.39
CDK2 P24941 1/20 0.39
MAPK8 P45983 1/20 0.39
MAPK9 P45984 1/20 0.39
MAPK10 P53779 1/20 0.39
TRPC3 Q13507 2/20 0.38
TRPC6 Q9Y210 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HPGD P15428 1/20 0.38
HTT P42858 1/20 0.38
RAB9A P51151 1/20 0.38
HSD11B1 P28845 1/20 0.37
KMT2A Q03164 1/20 0.37
ACHE P22303 1/20 0.37
GRM5 P41594 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3025237 0.80 FAAH (0.43) MGLLFAAHTRPC3TRPC6SMN1; SMN2
SCHEMBL3016226 0.79 HPGD (0.42) MGLLFAAHJUNCDK2MAPK8
SCHEMBL13246475 0.79 MGLL (0.62) MGLLFAAHSMN1; SMN2HPGDHTT
SCHEMBL5644769 0.78 MGLL (0.49) MGLLFAAHSMN1; SMN2HPGDHTT
SCHEMBL5640188 0.75 MGLL (0.49) MGLLFAAHSMN1; SMN2HPGDHTT
SCHEMBL3019969 0.75 HPGD (0.48) MGLLSMN1; SMN2HPGDHTTRAB9A
SCHEMBL5641596 0.74 FAAH (0.67) MGLLFAAH
SCHEMBL5641990 0.72 FAAH (0.47) MGLLFAAHSMN1; SMN2HPGDHTT
SCHEMBL3014204 0.71 MGLL (0.48) MGLLFAAHSMN1; SMN2HPGDHTT
SCHEMBL3024500 0.71 MGLL (0.48) MGLLFAAHSMN1; SMN2HPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190801-A1 TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES SANOFI-AVENTIS (FR) 2010-07-29 US disclosed
US-20100190801-A1 TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES SANOFI-AVENTIS (FR) 2010-07-29 US disclosed
US-20100190801-A1 TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES SANOFI-AVENTIS (FR) 2010-07-29 US disclosed
US-7718669-B2 Triazolopyridine derivatives as inhibitors of lipases and phospholipases SANOFI-AVENTIS (FR) 2010-05-18 US disclosed
US-7718669-B2 Triazolopyridine derivatives as inhibitors of lipases and phospholipases SANOFI-AVENTIS (FR) 2010-05-18 US disclosed
US-7718669-B2 Triazolopyridine derivatives as inhibitors of lipases and phospholipases SANOFI-AVENTIS (FR) 2010-05-18 US disclosed
US-20090030011-A1 TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES SANOFI-AVENTIS (FR) 2009-01-29 US disclosed
US-20090030011-A1 TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES SANOFI-AVENTIS (FR) 2009-01-29 US disclosed
US-20090030011-A1 TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES SANOFI-AVENTIS (FR) 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190801-A1 TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES PNLIP, LIPC, LPL MGLL 5/4885FAAH 150/4885JUN 3322/4885
US-20090030011-A1 TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES PNLIP, LIPC, LPL MGLL 5/4885FAAH 150/4885JUN 3322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.